Appointments at Sanofi-Aventis, MorphoSys and Ironwood Pharmaceuticals – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Pharma industry Pharmaceutical industry

in-PharmaTechnologist presents its latest round up of movements in the pharma space, including appointments at Sanofi-Aventis, MorphoSys and Ironwood Pharmaceuticals.

Sanofi-Aventis​ has appointed Hugh O’Neill ​as president and CEO of its Canadian operations. O’Neill has more than 23 years experience in the pharma industry and will now lead Sanofi’s efforts to “make a fundamental shift in the way [it does] business in Canada​”.

Before the appointment O’Neill served as vice president (VP), market access and business development at Sanofi in the US.

Thomas McCourt ​has joined Ironwood Pharmaceuticals​ as chief commercial officer and senior VP of marketing and sales. McCourt has previously worked at Amgen and Novartis.

Hygeia Therapeutics​ has appointed Elkan Gamzu​ as chairman of its board of directors. Gamzu has nearly 40 years experience in the pharma industry at companies including Pharmos, Millennium Pharmaceuticals and Hoffmann-LaRoche.

Hubert Chen ​has been appointed as VP of translational medicine at Regulus Therapeutics​. Chen will be responsible for translating microRNA discoveries into new medicines.

MorphoSys ​has appointed Lisa Rojkjaer ​as VP and head of clinical development. Rojkjaer joins MorphoSys from Novartis and has previously held positions at Novo Nordisk.

Elizabeth Cermak​ has been appointed as executive VP, chief commercial officer at Pozen​. Cermak will rake responsibility for the commercialisation strategies of all Pozen’s future product candidates.

Before joining Pozen Cermak spent 25 years at Johnson & Johnson, holding positions at Ortho-McNeil Pharmaceuticals, McNeil Consumer and Specialty Pharmaceuticals and other subsidiaries.

Clinical Data​ has elected Scott Tarriff ​to its board of directors. Tarriff has 25 years experience in the pharma industry, at companies including Par Pharmaceuticals and Bristol-Myers Squibb.

Mark Baker ​has been promoted to the newly created position of president of Progenics Pharmaceuticals​. Baker joined the company in 2005 and has also been appointed to the company’s board of directors.

Related topics Markets & Regulations

Related news

Show more